Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
ADVAIR HFA is a metered-dose inhaler combining fluticasone propionate (an inhaled corticosteroid) and salmeterol xinafoate (a long-acting beta-2 agonist) for inhalation. It is indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD), addressing both airway inflammation and bronchospasm. The combination works by reducing inflammation via the corticosteroid while providing sustained bronchodilation through the long-acting beta-agonist. ADVAIR HFA represents a foundational maintenance therapy approach in respiratory disease management.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Advair HFA in Healthy and HAPE Predisposed Subjects
Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)
A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spacer, And ADVAIR DISKUS
Worked on ADVAIR HFA at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
$398M Medicare spend — this is a commercially significant brand
Currently, zero open roles are linked to ADVAIR HFA. Career opportunities on this product are limited due to its mature lifecycle and approaching generification. Historically, the product created roles for brand managers, medical science liaisons, respiratory specialists, and field sales representatives, but these positions are declining as the product faces patent expiration. Professionals working on mature respiratory franchises typically require expertise in managed care negotiations, generic-to-brand transition strategy, and lifecycle extension tactics.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo